KORIO’s Post

Check out CRB's Yvonne Duckworth and Matt Edwards in the ISPE Baseline® Guide: Volume 8 – Pharma 4.0™. This guide is an excellent example of cross-industry collaboration to provide much-needed Industry 4.0 guidance. Check out the link below to read it. #LifeSciences #Industry40 #DigitalTransformation #ISPEFoF #ISPEFacilitiesOfTheFuture

Be sure to stop by booth #18 to meet with the EncompaaS team and discover how our solutions can elevate your pricing and contracting strategies. Plus, stay tuned for the reveal of our thought leadership session with EncompaaS' Chief Customer Officer David Gould! 📡⏳ #PricingAndContractingUSA #EncompaaS #informa #NewOrleans #rebatemanagement #ThoughtLeadershipSession 🚀

Check out CRB's Yvonne Duckworth and Matt Edwards in the ISPE Baseline® Guide: Volume 8 – Pharma 4.0™! This guide is an excellent example of cross-industry collaboration to provide much-needed Industry 4.0 guidance. As contributors, Yvonne and Matt collaborated with fellow industry experts to develop this comprehensive framework that offers tools and advice for companies looking to achieve successful and lasting digital transformations. Click the link below to read it. #LifeSciences #Industry40 #DigitalTransformation #ISPEFoF #ISPEFacilitiesOfTheFuture

Parexel’s regulatory and compliance CGMP experts are at the PDA/FDA Joint Regulatory Conference in DC . Read the latest update from my colleague Jo Wang.

I recently joined Charles Lee and Dr. Frank Ling on the Grok’s Radio Science Show to discuss the new world coming to cannabis medicine. Our conversation covered a range of topics, from the latest scientific discoveries to the implications of recent policy changes. Here are some key takeaways from our discussion: - Biden’s Reclassification: We covered the national impact of this significant policy shift and what it means for the future of cannabis research and medicine. - The Science of Cannabis: Highlighting cutting-edge research, including the relatively recent discovery of the Endocannabinoid System in 1992, which is still revealing its secrets and potential benefits, to anyone paying attention! - Medical and Legal Landscape: We discussed the evolving legal landscape and its effects on both medical research and the cannabis industry. - Future Prospects: Exploring what the latest scientific findings and policy changes could mean for medical professionals, researchers, and patients around the globe. This episode will soon be available on all popular podcast networks and broadcast on WHYR Baton Rouge. Don’t miss out on this insightful discussion, which promises to enlighten both seasoned experts and newcomers to the field of cannabis science. Preview the 18-minute clip here: https://lnkd.in/e-vDmwPy Whether you’re a professional in the medical field, a policy maker, or simply a curious mind, there’s something in this episode for everyone. We must push the boundaries of what we know and how we think about cannabis and its role in medicine and society!

Just read an insane stat: 25,000 people start using Wegovy in the US each week. Having a coherent GLP-1 strategy is a great first start to get ahead of the employee demand if teams want to implement on 1.1. CHROs + CFOs will want to model a few scenarios before they implement the drug before 1.1.25. We have seen some wonky spend stats on GLP-1s for teams who implemented midyear.

Our CEO, Kristina Torfgård, recently sat down with Redeye AB for an insightful interview discussing the upcoming rights issue and the latest progress within the company.   🎙️ Interview Highlights: - In-depth insights into the upcoming rights issue and what it means for our shareholders. - Updates on our recent advancements and strategic plans for the future. - Our vision and outlook for Alzinova AB’s role in the biopharmaceutical industry.   📌 Check out the full interview, link below!   #ALZ101 #CEOInterview #RightsIssue #Biopharma #AlzheimersResearch #CompanyUpdate

Phase XS - what is it all about is it forecasting or clinical trials analysis and does it help me understand from the perspective of portfolio management, IPR, clinical trials and more importantly does help achieve higher royalty period - to know more of this wait for our next bullitien in September

What to watch in Q3 and Q4.

🚀 20 years of speeding up your journey. And still accelerating. 🚀 Celebrating two decades of helping you comply with Good Manufacturing Practices. As a drug manufacturer, navigating the landscape of regulatory guidance during drug development can be challenging. You need to invest a vast amount of time and resources to gather information to ensure that the products you purchase meet your technical, regulatory and supply needs. 20 years ago, we launched the Emprove® Program to help accelerate your risk assessments and maintain your compliance with Good Manufacturing Practices. Since then, the program has evolved – and, to keep speeding up your journey, it is still accelerating.